Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Amortization period (in years) Intangible Asset, Finite-Lived, Remaining Amortization Period Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Purchase commitment renewal period Long-Term Purchase Commitment, Renewal Period Long-Term Purchase Commitment, Renewal Period Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Document Fiscal Year Focus Document Fiscal Year Focus Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Segment Reporting [Abstract] Debt instrument, face amount, fourth tranche Debt Instrument, Face Amount, Fourth Tranche Debt Instrument, Face Amount, Fourth Tranche Common stock, $0.01 par value; 200,000,000 shares authorized; 113,238,218 and 101,826,500 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued Accrued compensation and related benefits Employee-related Liabilities, Current Schedule of Long-Term Debt Instruments Schedule of Long-Term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Restatement Determination Date Restatement Determination Date Commercial milestone payments Collaboration Arrangement, Commercial Milestone Payment, Intellectual Property Rights Development, Maximum Collaboration Arrangement, Commercial Milestone Payment, Intellectual Property Rights Development, Maximum Derivative Instrument [Axis] Derivative Instrument [Axis] Issuance of common stock upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Fairmount Funds Management Fairmount Funds Management [Member] Fairmount Funds Management Initial conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding (in share) Entity Common Stock, Shares Outstanding July 1, 2024 through December 15, 2024 Debt Covenant Period Two [Member] Debt Covenant Period Two Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Debt Securities, Available-for-sale Debt Securities, Available-for-Sale [Table Text Block] Zenas BioPharma Zenas BioPharma [Member] Zenas BioPharma Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Foreign currency translation adjustment Change in cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Cash equivalents: Cash and Cash Equivalents [Abstract] Restricted stock units outstanding (in shares) Nonvested beginning balance (in shares) Nonvested ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Weighted-average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Initial Vesting Period Share-Based Payment Arrangement, Tranche One [Member] Accretion and amortization of available-for-sale securities Accretion (Amortization) of Discounts and Premiums, Investments Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Going Concern Going Concern, Policy [Policy Text Block] Going Concern [Policy Text Block] Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Total revenues License revenue Revenue from Contract with Customer, Including Assessed Tax Gross carrying amount Other Finite-Lived Intangible Assets, Gross Entity Address, City or Town Entity Address, City or Town Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Issuance of common stock upon exercises of warrants Stock Issued During Period, Value, Warrants Exercised, Value Stock Issued During Period, Value, Warrants Exercised, Value Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Basis of Presentation and Principles of Consolidation and Unaudited Interim Condensed Consolidated Financial Information Basis of Accounting, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Intangible asset, net Total Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount PURCHASE AND SALE OF THE REVENUE PARTICIPATION RIGHT Purchase And Sale Of Revenue Participation Right [Text Block] Purchase And Sale Of Revenue Participation Right Debt Covenant Period [Domain] Debt Covenant Period [Domain] Debt Covenant Period [Domain] Proceeds from issuance of common stock under employee stock purchase plan Proceeds from Stock Plans Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Other income (expense), net: Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] License revenue License License [Member] Sale of Future Revenue, Royalty Payments, Tier 3 Sale of Future Revenue, Royalty Payments, Tier 3 [Member] Sale of Future Revenue, Royalty Payments, Tier 3 Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Recently Issued Accounting Standard Updates New Accounting Pronouncements, Policy [Policy Text Block] Purchase of property and equipment included in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Schedule of Segment Reporting Information, by Segment Segment Reporting [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Research and development unpaid Research and Development Expense, Unpaid Research and Development Expense, Unpaid Related Party [Axis] Related and Nonrelated Parties [Axis] Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Convertible notes, net Long-Term Debt Paragon Therapeutics Paragon Therapeutics [Member] Paragon Therapeutics Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Preferred stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Preferred Stock, Shares Outstanding Loan received Debt Instrument, Face Amount CAPITAL STOCK Equity [Text Block] Security Exchange Name Security Exchange Name 2025 Employee Stock Purchase Plan 2025 Employee Stock Purchase Plan [Member] 2025 Employee Stock Purchase Plan Effective interest rate (in percent) Debt Instrument, Interest Rate, Effective Percentage Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Debt Conversion Terms One Debt Conversion Terms One [Member] Debt Conversion Terms One Total liabilities Liabilities, Fair Value Disclosure Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Operating lease liabilities, short-term Operating Lease, Liability, Current Accrued interest payable Interest Payable, Current NET LOSS PER SHARE Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Reportable Segment Reportable Segment [Member] Reportable Segment Long-term debt, net Secured Long-Term Debt, Noncurrent Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Unrecognized option employee stock-based compensation costs Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Sale of Future Revenue, Royalty Payments, Tier 1 Sale of Future Revenue, Royalty Payments, Tier 1 [Member] Sale of Future Revenue, Royalty Payments, Tier 1 Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Principal outstanding for redemption Debt Instrument, Convertible, Redemption Threshold Minimum Principal Amount Outstanding Debt Instrument, Convertible, Redemption Threshold Minimum Principal Amount Outstanding Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period Purchase commitment Long-Term Purchase Commitment, Amount Principal amount Long-Term Debt, Gross Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Other receivable Other Receivables, Net, Current Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Weighted-average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent U.S. treasury securities U.S. treasury securities US Treasury Securities [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Segment selling, general and administrative expense Selling, General And Administrative Expense, Excluding Share-Based Compensation Expense Selling, General And Administrative Expense, Excluding Share-Based Compensation Expense Vesting (in percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Tax benefit Share-Based Payment Arrangement, Exercise of Option, Tax Benefit Award Timing Predetermined Award Timing Predetermined [Flag] Intangible Asset, Goodwill and Other [Abstract] Intrinsic value of stock options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Convertible conversion ratio Debt Instrument, Convertible, Conversion Ratio ImmunoGen, Inc ImmunoGen, Inc [Member] ImmunoGen, Inc Outstanding beginning balance (in dollars per share) Outstanding ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value All Executive Categories All Executive Categories [Member] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Vesting [Domain] Vesting [Domain] Plan Name [Domain] Plan Name [Domain] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Issuance of common stock upon the conversion of convertible preferred stock Conversion of Stock, Amount Issued Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] SEGMENT INFORMATION Segment Reporting [Text Block] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Milestone achieved Milestone Achieved Milestone Achieved Denominator Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Schedule of Estimated Future Amortization Expense Intangible Asset, Finite-Lived, Amortization Expense [Table Text Block] Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Outstanding (Weighted Average Remaining Contractual Term) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Derivative [Table] Derivative [Table] Sale of Future Revenue, Royalty Payments, Tier 4 Sale of Future Revenue, Royalty Payments, Tier 4 [Member] Sale of Future Revenue, Royalty Payments, Tier 4 Proceeds from sale of common stock in at-the-market offerings Proceeds from Issuance of Common Stock Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Schedule of Restricted Stock Units Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Exercise Price Award Exercise Price Thereafter Intangible Asset, Finite-Lived, Estimated Amortization Expense, After Year Four Intangible Asset, Finite-Lived, Estimated Amortization Expense, After Year Four Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Issuance of common stock upon vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures WuXi Biologics (Hong Kong) Limited (“WuXi”) WuXi Biologics (Hong Kong) Limited (“WuXi”) [Member] WuXi Biologics (Hong Kong) Limited (“WuXi”) Kissei Pharmaceutical Co., Ltd Kissei Pharmaceutical Co., Ltd [Member] Kissei Pharmaceutical Co., Ltd Segment Reporting [Line Items] Segment Reporting [Line Items] Conditional payments, sales achievement threshold Debt Instrument, Conditional Payments, Sales Achievement Threshold Debt Instrument, Conditional Payments, Sales Achievement Threshold Maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Document Quarterly Report Document Quarterly Report Purchase commitment period Long-Term Purchase Commitment, Period Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Potential royalty payments Collaborative Arrangement, Potential Royalty Payments, Maximum Collaborative Arrangement, Potential Royalty Payments, Maximum Proceeds from sales of short-term investments Proceeds from Sale of Debt Securities, Available-for-Sale DEBT Debt Disclosure [Text Block] Prepayment of long-term debt Repayments of Long-Term Debt Conditional payments Debt Instrument, Conditional Payments Debt Instrument, Conditional Payments Unamortized debt discount and issuance costs Unamortized debt discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Measurement Input Type [Domain] Measurement Input Type [Domain] Secured Debt Secured Debt [Member] Aggregate offering Sale of Stock, Consideration Received on Transaction Adoption Date Trading Arrangement Adoption Date Debt instrument, face amount, third tranche Debt Instrument, Face Amount, Third Tranche Debt Instrument, Face Amount, Third Tranche Counterparty Name [Domain] Counterparty Name [Domain] Interest rate (in percent) Debt Instrument, Interest Rate, Stated Percentage Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Marketable securities: Short-Term Investments [Abstract] Total other income (expense), net Nonoperating Income (Expense) Assets Assets: Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Accrued outsourced clinical and nonclinical studies Accrued Outsourced Clinical and Nonclinical Studies, Current Accrued Outsourced Clinical and Nonclinical Studies, Current Payments of issuance costs associated with the sale of common stock Payments of Stock Issuance Costs Insider Trading Policies and Procedures [Line Items] Stock options outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Selling, general and administrative Selling, General and Administrative Expense Convertible Senior Notes Due 2032 Convertible Senior Notes Due 2032 [Member] Convertible Senior Notes Due 2032 COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of Operating Segments Restricted Stock Units Outstanding Restricted stock units Restricted Stock Units (RSUs) [Member] Schedule of Potentially Dilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key All Adjustments to Compensation All Adjustments to Compensation [Member] Elegrobart Elegrobart [Member] Elegrobart Equity [Abstract] Equity [Abstract] Proceeds from the issuance of common stock in offerings Proceeds from Issuance of Private Placement Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Income Statement [Abstract] Income Statement [Abstract] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Document Transition Report Document Transition Report Ownership [Axis] Ownership [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating expenses: Operating Expenses [Abstract] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Fair Value Assumptions for Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair value options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] City Area Code City Area Code Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Number of performance obligations Collaborative Arrangement, Number Of Performance Obligations Collaborative Arrangement, Number Of Performance Obligations Estimated fair value Debt Instrument, Fair Value Disclosure Name Forgone Recovery, Individual Name Remaining weighted-average period for stock options and RSUs Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] INTANGIBLE ASSET, NET Intangible Asset [Text Block] Debt Instrument, Convertible Terms Of Conversion [Domain] Debt Instrument, Convertible Terms Of Conversion [Domain] Debt Instrument, Convertible Terms Of Conversion [Domain] Statement [Line Items] Statement [Line Items] Total assets Assets March 2025 ATM Agreement March 2025 ATM Agreement [Member] March 2025 ATM Agreement Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Convertible notes, as converted to shares of common stock Convertible Debt [Member] Weighted average fair value per option (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Veligrotug Veligrotug [Member] Veligrotug Interest expense Interest Expense, Nonoperating Schedule of Allocation of Share-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Sale of Future Revenue, Agreed Upon Financial Terms Sale of Future Revenue, Agreed Upon Financial Terms [Member] Sale of Future Revenue, Agreed Upon Financial Terms Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax SHARE-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Proceeds from the sale of convertible notes Proceeds from Convertible Debt Issuance of common stock, net of issuance cost (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Share-based compensation expense Total share-based compensation expense Share-based compensation expense (see Note 11) Share-Based Payment Arrangement, Expense Other liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Issuance of common stock upon exercises of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Domain] Subsequent Event Type [Domain] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Through December 15, 2023 Debt Covenant Period One [Member] Debt Covenant Period One Accumulated Deficit Retained Earnings [Member] Total operating expenses Operating Expenses Money market funds Money Market Funds [Member] Liability related to the sale of future revenue, net Carrying value as of December 31, 2025 Carrying value as of June 30, 2026 Other Long-Term Debt, Noncurrent Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Series A Convertible Preferred Stock Series A Convertible Preferred Stock Series A convertible preferred stock, as converted to shares of common stock Series A Preferred Stock [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Stockholders’ deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Unrealized gain (loss) on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Payments of issuance costs associated with the sale of convertible notes Payments of Debt Issuance Costs Corporate paper and bonds Corporate Debt Securities [Member] Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Liabilities: Liabilities, Fair Value Disclosure [Abstract] Intangible Asset, Finite-Lived [Line Items] Intangible Asset, Finite-Lived [Line Items] Ownership [Domain] Ownership [Domain] Sale of Future Revenue, Royalty Payments, Tier 2 Sale of Future Revenue, Royalty Payments, Tier 2 [Member] Sale of Future Revenue, Royalty Payments, Tier 2 Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Long-Term Purchase Commitment [Line Items] Long-Term Purchase Commitment [Line Items] Accrued outsourced manufacturing Accrued Outsourced Manufacturing, Current Accrued Outsourced Manufacturing, Current Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Available-for-sale securities, term (less than) (in months) Debt Securities, Available-for-Sale, Term Financial Instruments [Domain] Financial Instruments [Domain] Schedule of Derivative Liabilities at Fair Value Schedule of Derivative Liabilities at Fair Value [Table Text Block] Debt instrument, face amount, fifth tranche Debt Instrument, Face Amount, Fifth Tranche Debt Instrument, Face Amount, Fifth Tranche Veligrotug, Drug Substance Veligrotug, Drug Substance [Member] Veligrotug, Drug Substance Issuance of common stock upon exercises of stock options Stock Issued During Period, Value, Stock Options Exercised Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Sale of Future Revenue, Milestone And Marketing Approval Sale of Future Revenue, Milestone And Marketing Approval [Member] Sale of Future Revenue, Milestone And Marketing Approval Underlying Securities Award Underlying Securities Amount Issuance of common stock, net of issuance cost Stock Issued During Period, Value, New Issues Over-Allotment Option Over-Allotment Option [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Sale of Future Revenue Sale of Future Revenue [Member] Sale of Future Revenue MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Financial Instruments Disclosure [Text Block] Preferred Stock Convertible Preferred Stock Preferred Stock [Member] Segment Reporting [Table] Segment Reporting [Table] Shares available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Debt Conversion Terms Two Debt Conversion Terms Two [Member] Debt Conversion Terms Two Sale of Stock [Axis] Sale of Stock [Axis] Weighted average remaining contractual term and Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] ACCRUED LIABILITIES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Change in fair value of derivative liability Change in fair value of derivative liability Change in fair value Derivative, Gain (Loss) on Derivative, Net Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Loss from operations Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date Proceeds from sale of future revenue Proceeds from Issuance of Debt Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Derivative [Line Items] Derivative [Line Items] 2016 Plan 2016 Employee Stock Purchase Plan [Member] 2016 Employee Stock Purchase Plan Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Milestones met Collaborative Arrangement, Rights And Obligations, Milestones Achieved Collaborative Arrangement, Rights And Obligations, Milestones Achieved Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted-Average Exercise Price Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] DESCRIPTION OF THE BUSINESS Business Description and Basis of Presentation [Text Block] 2020 Plan 2020 Plan [Member] 2020 Plan Marketable securities Debt Securities, Available-for-Sale, Current Equity Components [Axis] Equity Components [Axis] Related Party Related Party [Member] Product and Service [Domain] Product and Service [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Entity Interactive Data Current Entity Interactive Data Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Segment research and development expense Research And Development Expense, Excluding Share-Based Compensation Expense Research And Development Expense, Excluding Share-Based Compensation Expense Sales royalties threshold Debt Instrument, Royalty Payments Threshold Debt Instrument, Royalty Payments Threshold Termination Date Trading Arrangement Termination Date Collaboration revenue - related parties Collaboration Collaboration [Member] Collaboration [Member] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Collaborative arrangement, rights and licenses fee Collaborative Arrangement, Rights And Licenses Fee Collaborative Arrangement, Rights And Licenses Fee Expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other assets Other Assets, Noncurrent Document Type Document Type Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Non-cash interest expense Interest expense Paid-in-Kind Interest SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Sale of Future Revenue, Net Sales Achievement Sale of Future Revenue, Net Sales Achievement [Member] Sale of Future Revenue, Net Sales Achievement Exercisable (Aggregate Intrinsic Value) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies (Note 9) Commitments and Contingencies Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] 2030 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four Sale of Future Revenue, Milestone Sale of Future Revenue, Milestone [Member] Sale of Future Revenue, Milestone Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Long-Term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] 2026 Public Offering 2026 Public Offering [Member] 2026 Public Offering Collaboration arrangement, future developments milestone payment obligation Collaboration Arrangement, Future Developments Milestone Payment Obligation Collaboration Arrangement, Future Developments Milestone Payment Obligation Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Counterparty Name [Axis] Counterparty Name [Axis] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Exercisable (Weighted Average Remaining Contractual Term) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Award Type [Domain] Award Type [Domain] Accrued milestone payment Accrued Milestone Payment, Current Accrued Milestone Payment, Current Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 2027 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One Noncontrolling interest ownership (in percent) Subsidiary, Ownership Percentage, Noncontrolling Owner PEO Name PEO Name Threshold percentage of stock price trigger (in percent) Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Accrued and other liabilities Increase (Decrease) in Accrued Liabilities Cash, cash equivalents and short-term investments Cash, Cash Equivalents, and Short-Term Investments Other items Segment Reporting, Other Segment Item, Amount Payoff amount Repayments of Secured Debt Debt instrument, number of tranches Debt Instrument, Number Of Tranches Debt Instrument, Number Of Tranches Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Convertible notes, net Convertible Notes Payable, Noncurrent Warrants to purchase common stock Common Stock Warrants [Member] Common Stock Warrants [Member] Commission fee (in percent) Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accrued professional fees Accrued Professional Fees, Current Accounts payable Increase (Decrease) in Accounts Payable Other accrued liabilities Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Debt instrument, face amount, first tranche Debt Instrument, Face Amount, First Tranche Debt Instrument, Face Amount, First Tranche Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument [Axis] Debt Instrument [Axis] Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Collaboration arrangement, maximum milestone payments Collaboration Arrangement, Maximum Milestone Payments Collaboration Arrangement, Maximum Milestone Payments 2028 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two Purchase price of common stock, fair market value (in percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Issuance of common stock upon the conversion of convertible preferred stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Employee Stock Employee Stock [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Schedule of Balances by Plan Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Deferred revenue, current - related party Contract with Customer, Liability, Current Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Award Type [Axis] Award Type [Axis] Additional borrowing amount Debt Instrument, Accordion Feature, Increase Limit Debt Instrument, Accordion Feature, Increase Limit Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Threshold trading days Debt Instrument, Convertible, Threshold Trading Days Sales royalties, percentage Debt Instrument, Royalty Payments, Percentage Debt Instrument, Royalty Payments, Percentage Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Proceeds from term loan Proceeds from Issuance of Secured Debt Common Stock Common Stock [Member] Fair Value Short-term investments Debt Securities, Available-for-Sale Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Sale of Future Revenue, Marketing Approval Sale of Future Revenue, Marketing Approval [Member] Sale of Future Revenue, Marketing Approval Purchase commitment non-renewal notice, period prior to expiration of current term Long-Term Purchase Commitment, Non-Renewal Notice, Period Prior To Expiration Of Current Term Long-Term Purchase Commitment, Non-Renewal Notice, Period Prior To Expiration Of Current Term Series B Convertible Preferred Stock Series B Convertible Preferred Stock Series B convertible preferred stock, as converted to shares of common stock Series B Preferred Stock [Member] Derivative Contract [Domain] Derivative Contract [Domain] Equity Awards Adjustments Equity Awards Adjustments [Member] COLLABORATION AND LICENSE AGREEMENTS Collaborative Arrangement Disclosure [Text Block] Realized gains (losses) in available for sale securities Debt Securities, Available-for-Sale, Realized Gain (Loss) Total liabilities and stockholders’ equity Liabilities and Equity Derivative liability Derivative Liability, Noncurrent Allocation of net loss Net Income (Loss) Attributable To Parent, Allocation Net Income (Loss) Attributable To Parent, Allocation Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Segments [Axis] Segments [Axis] Other liabilities Increase (Decrease) in Other Operating Liabilities Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Plan Name [Axis] Plan Name [Axis] Related Party [Domain] Related and Nonrelated Parties [Domain] Derivative liability, measurement input Derivative Liability, Measurement Input Tabular List, Table Tabular List [Table Text Block] Vesting [Axis] Vesting [Axis] Additional paid-in capital Additional Paid in Capital Purchase agreement, volume requirement period Long-Term Purchase Commitment, Period, Volume Requirement Long-Term Purchase Commitment, Period, Volume Requirement 2029 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three Schedule of Components of Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] 2026 (remaining) Intangible Asset, Finite-Lived, Estimated Amortization Expense, Remainder of Fiscal Year Other income (expense), net Other expense, net Other Operating Income (Expense), Net Name Awards Close in Time to MNPI Disclosures, Individual Name Debt instrument, face amount, second tranche Debt Instrument, Face Amount, Second Tranche Debt Instrument, Face Amount, Second Tranche Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Outstanding (Aggregate Intrinsic Value) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Derivative Liability [Roll Forward] Derivative Liability [Roll Forward] Derivative Liability Valuation, Market Approach Valuation, Market Approach [Member] Sale of stock price (in dollars per share) Sale of Stock, Price Per Share Issuance of common stock upon conversion of convertible preferred stock Stock Issued During Period, Value, Conversion of Convertible Securities Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Milestone payments Collaboration Arrangement, Potential Milestone Payment, Maximum Collaboration Arrangement, Potential Milestone Payment, Maximum Class of Stock [Domain] Class of Stock [Domain] Non-cash lease expense Non-Cash Lease Expense Non-Cash Lease Expense Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total cash equivalents and marketable securities Assets, Fair Value Disclosure Name Measure Name Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Milestone and Royalty Payments Under In-licensing and Other Research & Development Agreements In Process Research and Development, Policy [Policy Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Future developments milestone payments Collaboration Arrangement, Milestone Payment, Intellectual Property Rights Development, Maximum Collaboration Arrangement, Milestone Payment, Intellectual Property Rights Development, Maximum Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Veligrotug, Drug Product Veligrotug, Drug Product [Member] Veligrotug, Drug Product Name Trading Arrangement, Individual Name Unrecognized employee stock-based compensation costs related to unvested RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Deferred issuance costs included in accounts payable and accrued liabilities Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Operating lease, liability, current, statement of financial position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Company Selected Measure Amount Company Selected Measure Amount Depreciation and amortization Depreciation, Depletion and Amortization Entity Address, Address Line Two Entity Address, Address Line Two Inducement Awards Inducement Grants [Member] Inducement Grants Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Current assets: Assets, Current [Abstract] Derivative liability Carrying value as of December 31, 2025 Carrying value as of June 30, 2026 Derivative Liability Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Collaborative arrangement, upfront fee payment Collaborative Arrangement, Upfront Fee Payment Collaborative Arrangement, Upfront Fee Payment Award Timing Method Award Timing Method [Text Block] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Issuance of common stock upon exercises of warrants (in shares) Stock Issued During Period, Value, Warrants Exercised, Shares Stock Issued During Period, Value, Warrants Exercised, Shares Research and development Research and Development Expense (Excluding Acquired in Process Cost) Net loss Net loss Net loss Consolidated net loss Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Statement [Table] Statement [Table] Subsequent Vesting Period Share-Based Payment Arrangement, Tranche Two [Member] Collaborative arrangement, rights and obligations, milestone payments Collaborative Arrangement, Rights And Obligations, Milestone Payment Collaborative Arrangement, Rights And Obligations, Milestone Payment Proceeds from the exercise of warrants Proceeds from Issuance of Warrants Restatement Determination Date: Restatement Determination Date [Axis] Proceeds from issuance of common stock upon exercises of stock options Proceeds from Stock Options Exercised Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Enable Injections Enable Injections [Member] Enable Injections Debt Instrument, Convertible Terms Of Conversion [Axis] Debt Instrument, Convertible Terms Of Conversion [Axis] Debt Instrument, Convertible Terms Of Conversion Interest income Investment Income, Interest Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Hercules Loan and Security Agreement Hercules Term Loan [Member] Hercules Term Loan Threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Revenues: Revenues [Abstract] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]